{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GS-5885&page=2", "query": { "intervention": "GS-5885", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GS-5885&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T07:30:41.823Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02350569", "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2015-05-22", "completion_date": "2016-04-22", "has_results": true, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-09-18T07:30:41.823Z", "location_count": 6, "location_summary": "San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02350569" }, { "nct_id": "NCT02707601", "title": "Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection", "HCV Infection" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "F/R/TAF", "type": "DRUG" }, { "name": "LDV/SOF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2016-04-01", "completion_date": "2017-09-29", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-09-18T07:30:41.823Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02707601" }, { "nct_id": "NCT01356160", "title": "GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "ribavirin tablet", "type": "DRUG" }, { "name": "GS-9451 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 351, "start_date": "2011-07", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-09-18T07:30:41.823Z", "location_count": 21, "location_summary": "Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01356160" }, { "nct_id": "NCT01726517", "title": "Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2012-10", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-18T07:30:41.823Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01726517" }, { "nct_id": "NCT02226549", "title": "Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "VDV", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2014-07", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-18T07:30:41.823Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02226549" }, { "nct_id": "NCT01768286", "title": "Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C Virus" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 441, "start_date": "2013-01", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-18T07:30:41.823Z", "location_count": 53, "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768286" }, { "nct_id": "NCT02301936", "title": "Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-03-02", "completion_date": "2016-04-18", "has_results": true, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-09-18T07:30:41.823Z", "location_count": 1, "location_summary": "Lutherville, Maryland", "locations": [ { "city": "Lutherville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02301936" }, { "nct_id": "NCT01193478", "title": "A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HCV Infection" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 71, "start_date": "2010-08", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2013-01-21", "last_synced_at": "2026-09-18T07:30:41.823Z", "location_count": 13, "location_summary": "Anaheim, California • Cypress, California • National City, California + 10 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Cypress", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193478" }, { "nct_id": "NCT02219685", "title": "Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "LDV/SOF", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 40, "start_date": "2014-08", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-18T07:30:41.823Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02219685" }, { "nct_id": "NCT01353248", "title": "GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "Tegobuvir", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "ribavirin tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 141, "start_date": "2011-05", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2013-12-20", "last_synced_at": "2026-09-18T07:30:41.823Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Anaheim, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01353248" } ] }